Previous 10 | Next 10 |
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 1, 2022 on Wednesday, August 10, 2...
Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...
STAAR Surgical Company presents the fundamental momentum that we feel can drive equity returns into the coming years. Profitability and cash flow metrics stack up well for the company, aligning with quality factors investors are now paying a premium for. As the growth trade exhaus...
There's a saying among stock traders: Don't try to catch a falling knife. And with the S&P 500 down by more than 22% this year so far and more market turmoil expected in the near future by practically everyone, investors are right to wonder whether they should be continuing to buy s...
Recent financial performance reported by Bausch + Lomb has been encouraging from a sales perspective. However, the company's bottom line is facing continued difficulties. But given how cheap shares of the business are today, it does seem to offer some upside potential even if risk...
Milestone Follows U.S. FDA Approval of EVO Visian® ICL in March EVO Offers Visual Freedom from Glasses and Contact Lenses STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems f...
STAAR Surgical Company (STAA) Q1 2022 Earnings Conference Call May 4, 2022 4:30 P.M. ET Company Participants Brian Moore - Vice President, Investor, Media Relations and Corporate Development Caren Mason - President and Chief Executive Officer Patrick Williams - Chief Financial Officer Confere...
STAAR Surgical press release (NASDAQ:STAA): Q1 Non-GAAP EPS of $0.29 beats by $0.14. Revenue of $63.2M (+24.5% Y/Y) beats by $2.67M. For further details see: STAAR Surgical Non-GAAP EPS of $0.29 beats by $0.14, revenue of $63.2M beats by $2.67M
EVO Visian® ICL Lenses Received FDA Approval and First Lenses Implanted STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the first...
With its share price down 56% in the past 12 months, STAAR Surgical 's (NASDAQ: STAA) stock has clearly seen better days. Judging by its collapse, it'd be reasonable to assume the implantable lens company is facing major headwinds -- but it isn't. In fact, there's not much standing ...
News, Short Squeeze, Breakout and More Instantly...
STAAR Surgical Company Company Name:
STAA Stock Symbol:
NASDAQ Market:
STAAR Surgical Company Website:
2024-07-14 17:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Will...
2024-05-24 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...